Esperion Directors Escape Investor Row Over Cholesterol Drug

February 19, 2020

An Esperion Therapeutics Inc. investor can’t sue the company’s directors derivatively for misstatements that allegedly led its stock to lose more than 50% in value, because he didn’t show it would have been futile to demand the company take action, the Delaware Chancery Court said.